BioInteractions celebrates its 30th anniversary
BioInteractions, a research and development company specialising in biomaterial technologies for the medical device industry, is celebrating its 30th anniversary.
Thirty years ago, BioInteractions founder Ajay Luthra had a dream to improve the effectiveness of biocompatible treatments to enhance patient therapies. He built BioInteractions to realise his vision to improve the application and lifetime of a wide range of medical devices including stents, valves, and catheters, by creating state-of-the-art materials that have become a critical factor behind the success of many of today's medical devices.
According to BioInteractions, coatings have just begun to shape the future of the industry. The company that enables most of the world’s leading medical device OEMs, has a bold plan for new products that keep efficacy, durability, and safety at the heart of their innovations.
This week the company celebrates the success of its first innovation – antithrombogenic material being developed into a biocompatible coating for medical devices. Over the decades, BioInteractions has grown as a critical partner with major manufacturers of healthcare technology by delivering key products that improve lubricity, anti-clotting, and antimicrobial protection for long periods of time; all are based upon its insight into biomaterials, blood chemistry and in the anatomical systems of the body. The coatings have featured as a component within solutions as diverse as the Affinity Oxygenator System and the Certofix Protect Catheter among many other devices.
Arjun Luthra, BioInteractions’ commercial director, said: “Over the last 30 years, the team at BioInteractions have been developing innovative biocompatible technology solutions that deliver an evolutionary step forward in medical devices and healthcare provision. Thanks to our innovations we have revolutionised patient care to such an extent that our solutions have aided the success of device related procedures, reduced the risk of rejection and minimised post operative infections. We are particularly proud of our track record on safety alongside efficacy. To date, thanks to our vigilant testing that is built-in to our manufacturing, we have never been required to recall a product. This pays tribute to my father’s legacy which aimed to improve well-being and reduce risks to both patients and professionals.”